1. Novo Nordisk's 2024 earnings exceeded estimates with 25% revenue growth; 2. The market overreacted to CagriSema trial results, leading to a 20% stock drop; 3. Despite the market's reaction, Novo Nordisk's shares offer attractive returns, leading to a Strong Buy rating.